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1. Introduction 
In the last decade, increasing interest in the role of nutrition in disease prevention has been 
observed. The World Health Organization (WHO) reported that one-third of all cancer 
deaths could be prevented, and that diet plays a key role in prevention (Bode & Dong, 2009). 
The term chemoprevention introduced and developed by Sporn (2005) and Wattenberg (1985) 
refers in general to multi-targeted pharmacological and nutritional intervention with the use 
of naturally occurring or chemically synthesized compounds. For this purpose, dietary 
phytochemicals believed to be safe for human use seem to be very promising. The 
importance of natural chemopreventive agents relies on their non-toxicity when given in 
small amounts for longer periods of time. Moreover, using a combination of phytochemicals 
provides synergistic or additive preventive effects.  
Cancer cell growth arises through a complex multistep process by which cancer cells acquire 
characteristics of unlimited proliferation potential, lack of response to growth signals, and 
resistance to cell death. Thus, preventive/therapeutic action of phytochemicals may be 
directed towards numerous molecular targets that are proteins involved in procarcinogen 
metabolism, cell transformation and proliferation, and signaling pathways leading to 
apoptosis of damaged or transformed cells (William et al., 2009). Targeting enzymes of the 
P450 superfamily may provide one of the strategies for enhancing the efficacy of 
chemopreventive and therapeutic agents (Swanson et al., 2010).  
Mechanistic studies of natural compounds are of great value regarding their characteristics 
of bioactivity, efficacy, selectivity and potential adverse side effects. Targeted inhibition of 
metabolic activation of carcinogens and induction of detoxifying enzymes has been 
considered a fundamental strategy for blocking the early stage of carcinogenesis. For 
example, inhibition of CYP1 enzymes was one test in the battery of assays employed in 
www.intechopen.com
 
Phytochemicals – A Global Perspective of Their Role in Nutrition and Health 
 
520 
screening of potential cancer chemopreventive agents (Gerhauser et al., 2003). Variable 
dietary exposure to phytochemicals may contribute to some of the inter-individual variation 
in the pharmacokinetics and pharmacological responses that are observed for drugs such as 
phenacetin, caffeine, and theophylline, which are substrates for CYP1A2 (Rendic & Di Carlo, 
1997). Further research is needed to determine the extent to which the effect of dietary 
exposure may be modified by genetic polymorphism of xenobiotic metabolizing enzymes. 
Phenolics are a diverse group of aromatic compounds broadly distributed in plants. Among 
this group, stilbenoids are compounds displaying multiple activities of interest with regard 
to cancer prevention and therapy, and their anticancer properties have been proven in 
various animal models (Szekeres et al., 2010). In this review, we summarize the results of 
studies on inhibitory activity of trans-resveratrol (3,4’,5-trimethoxy-trans-stilbene), the best 
recognized trans-stilbene (Figure 1), and its natural and synthetic analogues toward 
expression and activity of CYPs responsible for procarcinogen activation. We discuss the 
role of cytochrome family 1 inhibitors in cancer chemoprevention and chemotherapy. 
Additionally, we compare their effect with other natural phenols occurring in plant foods in 
relatively high amount and exerting significant bioactivity. Finally, we analyze the use of 
computational methods for biomolecular docking in structure and activity relationship 
studies of CYP1 inhibitors. 
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  R1 R2 R3 R4 
1. trans-Resveratrol H H H H 
2. Piceatannol H H OH H 
3. Rhapontigenin H H OH CH3
4. Desoxyrhapontigenin H H H CH3 
5. Pinostilbene H CH3 H H 
6. Pterostilbene CH3 CH3 H H 
Fig. 1. Structure of trans-resveratrol and its natural analogues 
2. Potential strategies targeting CYPs for cancer therapy and prevention 
One of the strategies of cancer chemoprevention is directed at drug-metabolizing enzymes 
such as cytochromes P450 (CYPs), a superfamily which metabolizes a wide spectrum of 
endogenous and exogenous substrates. Cytochrome P450 family 1 comprises three 
important isoforms: CYP1A1, CYP1A2 and CYP1B1 that catalyze the activation of 
procarcinogens such as polycyclic aromatic hydrocarbons, and aromatic and heterocyclic 
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amines. Additionally, CYP1B1 metabolizes 17-estradiol (E2) to 4-hydroxyestradiol (4-OH-
E2), which is further oxidized by peroxidase to estradiol-3,4-quinone to form a quinone-
DNA adducts responsible for estrogen-related carcinogenesis (Liehr et al., 1996). This 
pathway of metabolism is extensively studied with respect to polymorphism of CYP1 
enzymes and its association with carcinogenic metabolite formation (Kisselev et al., 2005). 
All members of the human CYP1 family are expressed in extrahepatic tissues. However, 
CYP1A2 is the only constitutive form of liver enzyme, and as such takes part in metabolism 
of xenobiotics, including numerous drugs (caffeine, theophylline, methadone, verapamil, 
propranolol, warfarin, tamoxifen). On the other hand, it is worth mentioning that microbial 
CYPs are considered as drug targets and may be used as biocatalysts in drug biosynthesis 
(Lamb et al, 2007). 
In humans, CYP1B1 is overexpressed in tumor cells, and this has important implications for 
tumor development and progression (Castro et al., 2008). It was found that CYP1B1 
knockout mice were highly resistant to 7,12-dimethylbenz[a]anthracene induced tumor 
formation (Gonzalez, 2002). Thus, regulators of the expression and catalytic activity of 
family 1 cytochromes appear to play an important role in cancer chemoprevention by 
blocking the initial stages of tumorigenesis. With respect to cancer chemotherapy, CYP1A1 
and CYP1B1 have the ability to metabolize cytostatics, diminishing their toxic effect on 
cancer cells (McFadyen & Murray, 2001). Considering this, the inhibition of CYP1B1, an 
enzyme up-regulated in many cancers, would be a strategy to prevent the loss of cytostatics 
effectiveness. On the other hand, the development of anticancer prodrugs specifically 
activated by CYP1B1 to cytotoxic compounds might be a promising novel strategy in cancer 
chemotherapy (Bruno & Njar, 2007).  
3. Mechanism of the expression of CYP1 genes – AHR as a target for 
effective chemopreventive approach 
Members of the CYP1 family are under the transcriptional control of the aryl hydrocarbon 
receptor (AHR) localized in cytosol that is activated by polyhalogenated aromatic 
hydrocarbons, among them 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). AHR agonists are 
well known environmental pollutants. As a result of activation AHR translocates into the 
nucleus and forms a dimer with ARNT (aryl hydrocarbon nuclear translocator). The 
AHR/ARNT complex is characterized by a high affinity to specific DNA recognition sites 
termed DREs (dioxin response elements) or AHREs (aryl hydrocarbon response element) 
which upregulate a battery of target genes, including those involved in metabolism of 
chemical carcinogens such as CYP1A1, CYP1A2 and CYP1B1 (Fig. 2). In this way, agonists 
induce the expression of xenobiotic metabolizing enzymes (XMEs) that activate 
procarcinogens to genotoxic forms. Thus, the treatment with AHR antagonists by 
preventing this undesirable effect might be a chemopreventive strategy. 
There are phytochemicals that possess the ability to block agonist interaction with the 
ligand-binding site of the AHR and agonist induction of the AHR-signaling pathways. In 
that respect, resveratrol is the best recognized stilbene derivative. Moreover, it is one of the 
best-characterized chemopreventive phytochemicals (Goswami and Das, 2009). It occurs 
mainly in small fruits like berries and grapes, peanuts and red wine. Its chemopreventive 
properties found in studies on animals in vivo were described for the first time by Jang and 
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Fig. 2. AHR signaling pathway; L – ligand; Hsp90 – heat shock protein 90; ARNT – aryl 
hydrocarbon nuclear receptor; AHRE – aryl hydrocarbon response element. AHR/ARNT 
complexes bind to the DNA recognition sequence AHRE located in regulatory regions of 
phase I (CYP1A1, CYP1A2, CYP1B1) and phase II drug metabolizing enzymes. 
coworkers (Jang et al., 1997). Chen and collaborators have reported that resveratrol strongly 
inhibited TCDD-induced AHR binding activity in human mammary epithelial (MCF-1-A) 
cells (Chen et al., 2004). The inhibition of CYP1A1 expression by resveratrol was observed in 
rat primary hepatocytes (Andrieux et al., 2004). In human HepG2 hepatoma cells, 
resveratrol inhibited the increase in CYP1A1 mRNA caused by TCDD in a concentration-
dependent manner. The induction of transcription of an aryl hydrocarbon-responsive 
reporter vector containing the CYP1A1 promoter by TCDD was likewise inhibited by 
resveratrol. Resveratrol also inhibited the constitutive level of CYP1A1 mRNA and reporter 
vector transcription in human hepatoma HepG2 cells (Ciolino et al., 1998). Resveratrol was 
also effective in inhibiting CYP1A1 transcription induced by the aryl hydrocarbon 
dimethylbenz[a]anthracene in human mammary carcinoma MCF-7 cells and B[a]P-treated 
HepG2 cells (Ciolino et al., 1999). These data demonstrate that resveratrol inhibits aryl 
hydrocarbon-induced CYP1A activity in vitro by directly inhibiting CYP1A1/1A2 enzyme 
activity, and by inhibiting the signal transduction pathway that up-regulates the expression 
of carcinogen activating enzymes. The antagonistic action of resveratrol was supported by in 
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vivo experiments on phytochemicals with four different structures, where only resveratrol 
given topically on mouse epidermis inhibited aryl hydrocarbon hydroxylase (AHH) activity 
in a dose dependent manner (Table 1) (Szaefer et al., 2004). Moreover, resveratrol has been 
shown to prevent genotoxicity of B[a]P by inhibiting B[a]P-induced CYP1A1 expression and 
BPDE-DNA adduct formation in the lungs of mice (Revel et al., 2003).  
 
Treatment Dose Activity [pmol/min/mg 
protein] 
Acetone 0.2 ml 65.3  4.6 
5,6-Benzoflavone 8 M 336  17.2 
Protocatechuic acid 8 M 75.3  2.1 
 16 M 83.4  6.4 
Chlorogenic acid 8 M 71.7  3.2 
 16 M 83.9  2.8 
trans-Resveratrol 8 M 18.9  2.6 
 16 M 0.08  0.01 
Table 1. Effect of phenolic compounds on mouse epidermal AHH activity 
Summarising, resveratrol inhibits AHR-dependent transcription by preventing AHR/ARNT 
binding to the AHRE. The activity of preventing the conversion of ligand-bound cytosolic 
AHR into its nuclear DNA-binding form and/or the interaction between the AHR and the 
transcription initiation complex at the CYP1A1 gene promoter may be an important part of 
the chemopreventive activity of resveratrol. However, the action of resveratrol is not specific 
because this natural stilbene as a phytoestrogen is also a potent ER (estrogen receptor) 
agonist. Recently, experiments on human breast cancer cells revealed that the estrogenic 
properties of resveratrol and its influence on the ER expression are independent of its ability 
to inhibit the expression of genes controlled by AHR (MacPherson & Matthews, 2010). New 
stilbene derivatives of resveratrol that were synthesized appeared to be selective for AHR 
and devoid of affinity for ER. Among the trans-stilbenes synthesized, all displayed a 
significantly higher affinity than resveratrol for AHR. Substitution of 3- and/or 5-hydroxy 
groups with chlorine atoms coupled with replacement of 4’-hydroxy with chlorine or a 
methoxy group yielded selective TCDD antagonists with high affinity for the AHR that was 
much higher than resveratrol. Interestingly, one of the studied compounds, 3-hydroxy-5-
chloro-4’-trifluoromethyl-trans-stilbene, was a selective AHR agonist exerting extremely 
high-affinity to AHR with a Ki of 0.2 nM. None of the compounds studied showed any 
detectable affinity for the ER that should eliminate estrogen-related risks, such as the 
increased risk of ER-related cancers (de Medina et al. 2005). 
In the Table 2 we summarized the studies on the effects of resveratrol and its derivatives on 
AHR related expression of CYP1 enzymes. However, the results of in vivo experiments on 
animals are highly dependent on the dose of a studied compound, as well as the duration 
and manner of its administration. Further, the effect of a studied substance may also be 
tissue-dependent. The expression of CYP1A1 and CYP1A2-related monooxygenases in 
hepatic subcellular preparations from resveratrol treated male mice did not differ from the 
control; while in pulmonary subcellular preparations significantly lower expression of 
CYP1A1/2 –dependent enzymes was observed (Canistro et al., 2009).  
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Effect Compound Experimental Model 
 
References 
AHR translocation  
AHRE transactivation  
resveratrol 47DRE reporter cell 
line 
Casper et al., 1999 
AHR DNA binding , 
expression and activity of 
CYP 1A1/1B1  
resveratrol TCDD-treated MCF-
10A cells 
Chen et al, 2004 
Expression and activity of 
CYP1A1/1A2  
resveratrol B[a]P-treated HepG2 
cells and DMBA-
treated MCF-7 cells 
Ciolino et al., 1999 
CYP1A1 expression  
Induction of transcription of 
AHR reporter vector 
containing the CYP1A1 
promoter by TCDD  
constitutive level of CYP1A1 
mRNA and reporter vector 
transcription  
resveratrol TCDD treated human 
HepG2 cells 
 
Ciolino et al., 1998 
 
CYP1A1 expression  
BPDE-DNA adduct 
formation  
resveratrol lung tissue from BP-
treated mice 
Revel et al., 2003 
CYP1A1 expression by 
resveratrol  
resveratrol rat primary 
hepatocytes 
Andrieux et al., 
2004 
AHR binding ability of 
resveratrol and its 
derivatives  
resveratrol and 
24 other 
stilbenes 
47DRE reporter cell 
line 
de Medina et al., 
2005 
 
Expression of human 
CYP1A1 and CYP1B1  
Recruitment of the AHR 
complex and RNA 
polymerase II to the 
regulatory regions  
resveratrol TCDD-induced 
human breast cancer 
cell line MCF-7, and 
human hepatocellular 
carcinoma cell line, 
HepG2 
Beedanagari et al., 
2009 
AHR-dependent 
transcription of CYP1A1 
and CYP1B1  
resveratrol TCDD-induced 
human breast cancer 
cells T-47D 
MacPherson and 
Matthews, 2010 
CYP1A1 and CYP1B1 
expression  
Recruitment of AHR and 
ARNT to CYP1A1 and 
CYP1B1 enhancer regions  
piceatannol TCDD-induced 
human breast cancer 
cells T-47D 
MacPherson and 
Matthews, 2010 
Table 2. AHR as a molecular target for chemopreventive action of resveratrol and its 
derivatives 
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4. Inhibitory effect of stilbene derivatives on CYP1A enzymes 
4.1 Trans-resveratrol 
The studies of the inhibitory effect of phytochemicals on cytochrome P450 dependent 
enzymes are mainly conducted with the use of in vitro techniques on cDNA-expressed 
enzymes. Recombinant biscistronic supersomes express particular CYP activity and 
cytochrome c reductase activity. It was reported that resveratrol inhibited human 
recombinant P450 1A1 activity in a competitive manner (Chun et al., 1999), but the IC50 
value (the concentration that causes 50% inhibition of enzyme activity) of 23 M was much 
higher than the IC50 value of 1.4 M obtained for CYP1B1 inhibition (Chang et al., 2000). 
Interestingly, resveratrol inactivated human recombinant CYP1A2 indirectly in a 
mechanism-based manner (Chang et al, 2001).  
Mechanism-based inhibition was not observed in rat liver microsomes; EROD (7-
ethoxyresorufin-O-deethylase) activity as an indicator of both CYP1A1 and CYP1A2 was 
inhibited by resveratrol and piceatannol (3,3’,4,5’-tetrahydroxy-trans-stilbene) with Ki value 
of 0.4 M for both compounds and a mixed type of inhibition (Chang et al., 2007). It was 
found that resveratrol is metabolized to piceatannol in the reaction of hydroxylation 
catalyzed by CYP1A2 (Piver et al. 2004) and CYP1B1 (Potter et al. 2002). Poor bioavailability 
of resveratrol caused by its fast metabolism to glucuronides and sulphates limits the use of 
this stilbene as a potent chemopreventive / chemotherapeutic agent (Walle et al., 2004). To 
explain the bioactivity of resveratrol, its accumulation to active levels in target organs or 
synergistic / additive effects with other food components are taken into account. 
4.2 Natural resveratrol analogues 
During the last decade, other naturally occurring stilbenoid compounds with potential 
health benefit were found and examined. Piceatannol and pterostilbene (3,5-dimethoxy-4’-
hydroxy-trans-stilbene) occur mainly in grapes and blueberries, with their amount 
depending on plant variety (Rimando et al., 2004). Pterostilbene that was shown to have 
cancer chemopreventive activity similar to resveratrol (Rimando et al., 2002) occurs also in 
some medicinal plants used in traditional medicine. Beneficial bioactivity of natural 
resveratrol analogues have been demonstrated in numerous in vitro experiments and in 
preclinical animal models (Rimando and Suh, 2008). Resveratrol analogues exert multiple 
bioactivities involved in cancer chemoprevention; for example, they are efficient inhibitors 
of family 1 cytochromes. The inhibitory action of natural stilbenes appears to be highly 
selective depending on the cytochrome isoform. Moreover, the extent of CYP inhibition 
changes according to the stilbene structure; the types and positioning of functional groups 
linked to the stilbene scaffold significantly influence inhibitory activity of stilbene 
derivatives. Rhapontigenin (3,5,3’-trihydroxy-4’-methoxystilbene) was found to be a very 
selective and potent inactivator of CYP1A1 activity with IC50 value 0.4 M and Ki value of 
0.09 M (Chun et al., 2001a). Pinostilbene (3,4’-dihydroxy-5-methoxy-trans-stilbene), 
pterostilbene and desoxyrhapontigenin (3,5-dihydroxy-4’-methoxy-trans-stilbene) were 
more efficient inhibitors of CYP1A1 and CYPA2 in comparison to the parent compound, 
while they inhibited CYP1B1 to the same extent as resveratrol (Guengerich et al., 2003; 
Mikstacka et al., 2006, 2007). The data on the inhibition of CYP1 enzymes by natural 
stilbenes are summarized in Table 3. 
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4.3 Resveratrol methyl ethers and other synthetic stilbenes 
In the last decade, new stilbene derivatives have been designed and synthesized in order to 
find more potent chemopreventive agents (Szekeres et al., 2010). The additional aim of this 
approach was to find resveratrol derivatives demonstrating better bioavailability in 
comparison to the parent compound. The bioactivity of resveratrol analogues could be 
altered due to the presence and positioning of methoxy groups on the basic resveratrol 
backbone that prevent the conjugation reaction with sulphuric and glucuronic acids. 
Synthesized derivatives are tested with regard to their inhibitory activity toward CYP 1 
enzymes in order to find more efficient and selective inhibitors. A series of trans-stilbene 
derivatives containing a 3,5-dimethoxyphenyl moiety were prepared and evaluated on 
human recombinant CYP1A, CYP1A2 and CYP1B1 to find a potent and selective CYP1B1 
inhibitor. It was shown that substitution at the 2-position of the stilbene skeleton plays a 
very important role in discriminating between CYP1A1/2 and CYP1B1. Chun and his group 
found 3,5,2’,4’-tetramethoxy-trans-stilbene as a new selective and very potent inhibitor of 
human CYP1B1 (Chun et al., 2001b). Among the whole series of compounds tested, 3,5,2’,4’-
tetramethoxy-trans-stilbene exerted the most potent inhibitory activity toward CYP1B1 with 
an IC50 value of 2 nM. 2-[2-(3,5-dimethoxyphenyl)vinyl]tiophene showed comparable 
inhibitory activities, but its selectivity toward CYP 1B1 was lower (Kim et al. 2002).  
Another series of stilbenes with 4-methylthiophenyl moiety were synthesized and their 
inhibitory potency toward human recombinant CYPs: CYP1A1, CYP1A2 and CYP1B1 was 
evaluated. Among compounds tested, 2-methoxy-4’-methylthio-trans-stilbene and 3-
methoxy-4’-methylthio-trans-stilbene demonstrated the most potent and selective inhibitory 
effect on CYP1A1 and CYP1B1 activities (Mikstacka et al, 2008). 
 
Compound 
CYP1A1 CYP1A2 CYP1B1 
Ki 
[M] 
Mode of 
inhibition 
Ki  
[M]
Mode of 
inhibition 
Ki 
[M]
Mode of 
inhibition 
Resveratrol 
 
1.2a mixed type 15.5a 
5.33c 
mixed type 0.75a mixed type 
Piceatannol 
 
3.01 competitive 9.67c mixed type 0.27 competitive 
Desoxyrhapontigenin
 
0.16 competitive 1.04 mixed type 2.06 competitive 
Pinostilbene 
 
0.13 mixed type 0.94 mixed type 0.90 competitive 
Pterostilbene 
 
0.57 competitive 0.39c mixed type 0.91 competitive 
Rhapontigenin 
 
0.21b 
0.4 
(IC50) 
competitive  
160 
(IC50)
n.d.  
9 
(IC50)
n.d. 
a Chang et al., 2001; b Chun et al., 2001; c in mouse liver microsomes (Mikstacka et al., 2006); n.d. not 
determined 
Table 3. Effect of natural trans-stilbenes on human recombinant CYP1A1, CYP1A2 and 
CYP1B1 activities 
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4.4 Other natural phenols 
The influence of other phenolic phytochemicals on CYP1 activities is worth presenting in the 
context of possible additive or synergistic effects of the micro-components of human diet. 
The properties of plant extracts rich in numerous bioactive substances are particularly 
interesting in terms of herb-drug interaction, which could be a subject of independent 
review. At the beginning of the last decade, Piver and collaborators (2003) discovered that 
non-volatile components of red wine or various Cognac beverages exert stronger inhibitory 
effect on CYP1A1, CYP1A2, and CYP1B1 than resveratrol and its dimer ε-viniferin. Another 
extract, prepared from the most widely used herbal medicine Ginkgo biloba, was tested for its 
ability to inhibit the major human cytochrome P450 enzymes (Gaudineau et al., 2004). It was 
demonstrated that the flavonoidic fraction of standardized extract inhibits human CYP1A2 
and other cytochromes (CYP2C9, CYP2E1, and CYP3A4), wheras its terpenoidic fraction 
significantly inhibits only CYP2C9. In vivo CYP1A2 induction was observed as a result of 
herbal dietary supplementation (Rye et al., 2003). Effects of Cuban and Mexican herbal 
extracts used in traditional medicine (obtained from Heliopsis longipes, Mangifera indica L. 
and Thalassia testudinum) on CYP1A1/2 and other cytochromes involved in drug 
metabolism of CYP3A4 and CYP2D6 were studied with the use of human liver microsomes 
and compared with the pure constituents isolated from the extracts of affinin (an alkamide 
isolated from the H. longipes extract), N-iso-butyl-decanamide, and mangiferin. The extracts 
significantly inhibited CYP1A1/2 activities, which reflects the high content of flavonoids 
with recognized CYP1A1/2 inhibitory properties (Rodeiro et al., 2009). 
Numerous natural phenols demonstrate inhibitory activity toward CYP1 enzymes. 
Phytochemicals that exert inhibitory effects on CYP1A enzymes comparable to natural 
stilbenes comprise: flavonoids, isothiocyanates, coumarin and its derivatives. 
Flavonoids represent a large class of phenolic phytochemicals. They are ubiquitously 
present in plant-derived foods and are important microcomponents of the human diet. 
Humans ingest approximately 0.6-1 g of these bioactive compounds daily (Kuhnau, 1976). 
The effects of flavonoids on CYP1 activities have been explored since the early nineties, 
including the effects of flavone and five hydroxylated derivatives on the methoxyresorufin 
O-demethylase activity catalyzed by human recombinant CYP1A1 and CYP1A2 (Zhai et al., 
1998). The authors found galangin (3,5,7-trihydroxyflavone) as the most potent inhibitor of 
CYP1A2 with Ki value of 8 nM. It should be mentioned that no stilbene derivative with a 
comparable inhibitory potency toward CYP1A2 was found. Furthermore, galangin showed 
almost 5-fold selectivity for CYP1A2 over CYP1A1; while, 7-hydroxyflavone exhibited 6-fold 
greater selectivity for CYP1A1 over CYP1A2. The other hydroxylated flavone derivatives: 3-
hydroxy; 5-hydroxy; 7-hydroxy- and 3,7-dihydroxyflavone were also potent inhibitors of 
CYP1A1 (IC50 < 0.1 µM) and CYP1A2 (IC50 < 0.3 µM).  
In experiments with the use of human recombinant CYPs, seven flavonoids (myricetin, 
apigenin, kaempferol, quercetin, amentoflavone, quercitrin, and rutin) occurring in St. 
John’s Wort were tested. They were found to be slightly more selective for CYP1B1 activity 
compared to CYP1A1. Apigenin and amentoflavone were competitive inhibitors of CYP1B1, 
while quercetin showed a mixed type of inhibition. The most potent CYP1B1 inhibitor was 
apigenin with Ki of 60 nM. The same authors investigated CYP1 inhibition in cell system. 
Myricetin, apigenin, kaempferol and quercetin inhibited TCDD-induced EROD activity in 
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intact 22Rv1 human prostate cancer cells. Because flavonoids were added 30 minutes prior 
to the EROD assay, the inhibition did not reflect down regulation of CYP1 mRNA or protein 
level (Chaudhary et al., 2006). The influence of flavonoid constituents of St. John’s Wort 
were also studied by Schwarz’s group. They demonstrated the differentiated inhibition of 
CYP1A1-catalyzed estradiol 2-hydroxylation according to CYP1A1 genotype. The variant 
CYP1A1.2 (Ile462Val) was significantly inhibited by quercetin, hypericin and 
pseudohypericin (naphthodiantrones), with IC50 values for 2-hydroxylation being more than 
two times lower than the wild-type enzyme. Additionally, the wild-type enzyme was 
efficiently inhibited by kaempferol, myricetin and resveratrol (Schwarz et al., 2011). 
The synthesis of structures differentiated by type and positions of substituents leads to a 
continuation of structure and activity relationship (SAR) studies. Recently, Takemura and 
coworkers (2010) evaluated the structure–property relationship of 18 major flavonoids on 
inhibiting enzymatic activity of CYP1A1, 1A2 and 1B1 by using an ethoxyresorufin O-
deethylation assay. Flavones and flavonols indicated relatively strong inhibitory effects 
on CYP1s compared with flavanone that does not have the double bond between C-
positions 2 and 3 on the C-ring. Flavonoids used in this study selectively inhibited 
CYP1B1 activity. 
Special attention is paid to methoxy derivatives of flavone, which have inhibitory potency 
exceeding that of the parent compound (Walle & Walle, 2007). In particular, methoxy types 
of flavones and flavonols such as chrysoeriol and isorhamnetin showed strong and selective 
inhibition against CYP1B1 (Takemura et al., 2010). The most potent inhibitors of CYP1 
catalyzed ethoxyresorufin O-deethylation were the methoxylated flavones acacetin, 
diosmetin, eupatorin and the dihydroxylated flavone chrysin, indicating that the 4’-OCH3 
group at the B ring and the 5,7-dihydroxy motif at the A ring play a prominent role in EROD 
inhibition (Androutsopoulos et al., 2011). It was observed that high metabolic turnover of 
methoxylated flavonoids may result in enhanced antiproliferative activity. Several flavonoid 
metabolites produced in reactions catalyzed by CYP1A1 or CYP1B1 have been shown to 
inhibit cancer cell cycle progression. The authors observed CYP1A1-catalyzed 
biotransformation of acacetin to luteolin, apigenin and scutellarein. The chemopreventive 
ability of these metabolites was previously established. Generally, it is suggested that 
dietary flavonoids exhibit three distinct modes of action with CYP1 enzymes: (1) inhibitors 
of CYP1 enzymatic activity, (2) CYP1 substrates and (3) substrates and inhibitors of CYP1 
enzymes. 
Coumarin (1,2-benzopyrone) and its derivatives occur naturally in several plant families. 
They are components of essential oils, and are often used as fragrance ingredients in human 
diet. Their effect on CYP1 activities have been studied since the early nineties. The naturally 
occurring coumarins: bergamotin, coriandrin, isoimperatorin, imperatorin, ostruthin are 
potent inhibitors of the metabolic activation of benzo(a)pyrene and dimethylbenzanthracene 
in the cell culture model system of mouse epidermis (Cai et al., 1997). In experiments in 
vitro, mechanism-based inactivation of hepatic EROD activity by natural coumarin 
coriandrin was observed (Cai et al., 1996). These results demonstrate that certain coumarins 
to which humans are exposed in their diet are bioactivated by CYP1A1 to reactive 
intermediates that subsequently form covalent adducts with the apoprotein, effectively 
destroying enzyme activity. 
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Curcumin is a natural plant food additive obtained from turmeric used in spices and 
traditional Indian medicine. Its chemopreventive anticancer potential is well documented 
(Aggarwal et al., 2003). It belongs to hydroxycinnamic acid derivatives observed 
ubiquitously in plants. Earlier reports on the inhibition of rat liver microsomal CYPs by 
curcumin showed that curcumin is a strong inhibitor of CYP1A enzymes and CYP2B as well 
(Oetari et al., 1996; Thapliyal and Maru, 2001, 2003). However, these data were not 
confirmed in studies with human recombinant cytochrome P450s, where curcumin 
appeared to be a moderate inhibitor of CYP1A2 with IC50 value 40 M (Appiah-Opong et al., 
2007). Appiah-Opong and coworkers synthesized curcumin derivatives that exhibited about 
10- to 40-fold greater potency towards inhibition of CYP1A2 than curcumin itself (Appiah-
Opong et al., 2008). 
Other natural phenols studied more recently with respect to CYP1 inhibition include 
phytocannabinoids, constituents of marijuana, and chromene amides from Amyris plumieri, 
a plant grown in the Caribbean, Central America and Venezuela used in folk medicine. 
Three major constituents in marijuana; 9-tetrahydrocannabinol, cannabidiol and cannabinol 
inhibited activities of human recombinant CYP1s: CYP1A1, CYP1A2 and CYP1B1 in a 
competitive manner (Yamaori et al., 2010). One of the amides (chromene acetamide) tested 
appeared to inhibit potently CYP1A1 activity in vitro with IC50 and Ki values 1.547 M and 
0.37 M, respectively (Badal et al., 2011). 
Interestingly, in the studies on different natural phenols Schwarz and Roots demonstrated 
that the inhibitory effect depends not only on the structure of the inhibitor, but also the 
substrate of the reaction catalyzed by CYPs used in the assay. They found flavonoids like 
myricetin, apigenin, quercetin, and kaempferol, as well as tea polyphenol (-)epigallo 
catechin gallate, strongly inhibited the formation of benzo(a)pyrene diolepoxide, the 
ultimate carcinogenic product of benzo(a)pyrene activation. Furthermore, resveratrol, an 
inhibitor of CYP1A1-catalyzed ethoxyresorufin deethylation, exhibited only slightly 
inhibitory effect on CYP1A1-mediated epoxidation of 7,8-diol-B(a)P (Schwarz & Roots, 
2003). 
5. Docking studies – The new approach to CYPs-phytochemical interaction 
Mechanistic studies of the inhibitory effect of stilbenes on enzyme activities are mainly 
conducted in vitro with the use of human recombinant cytochromes. However, the affinity of 
compounds to cytochromes may be determined by computational analysis of 
inhibitor/substrate docking in the enzyme active site. Molecular modeling is presumed to 
be helpful in predicting inhibitory potential of CYP regulators by characteristics of ligand-
enzyme interactions. We review in silico research on elucidating the mechanism of inhibitory 
action of phytochemicals by analysis of structure and activity relationship. Potential 
phytochemical candidates can be selected by in silico virtual screening, based on natural 
compound libraries (www.bioscreening.com). When active chemicals are selected, they may 
be “docked” into the target protein by using available programs, enabling detailed protein-
ligand interactions to be obtained and the best fit of a candidate compound to be identified. 
The main objective of molecular docking is to determine the binding interactions between 
protein and ligand.  
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Computational procedures of molecular modeling have been employed since the nineties. 
Studies of Lewis and coworkers (1997) on CYP1 family enzymes structure and ligand 
docking in enzyme cavities have been a great contribution to the development of this field. 
Lewis formulated the general characteristic of CYP1 ligands as planar and polar polycyclic 
molecules. Substituents linked to the polycyclic hydrocarbon core influence the ligand 
binding responsible for molecular interactions: hydrogen bonds; - stacking; and 
hydrophobic interactions. The effect of structural modification on the inhibitory selectivity 
of phytochemical derivatives on CYP1A1, CYP1A2, and CYP1B1 help to elucidate which 
interactions determine the inhibitory ability of the compounds. There are similarities 
between the active sites of CYP1A2 and CYP1A1 which are in accordance with the 
overlapping substrate specificities of the two enzymes. However, the CYP1A1 substrates are 
generally of higher lipophilicity than those of CYP1A2. The reason lies in the more 
hydrophobic character of the CYP1A1 active site region (including the access channel) in 
comparison to CYP1A2 active site (Lewis et al., 1999). The differences in the structure of 
enzyme binding sites may determine the metabolism pathways of a substrate. With the use 
of computational docking the mechanism of E2 2-hydroxylation and 4-hydroxylation 
catalyzed by CYP1A1/2 and CYP1B1, respectively, were elucidated. CYP1A1 and CYP1A2 
produced 2-OH-E2 and 4-OH-E2 in a ratio of 10 : 1; whereas CYP1B1 produces 2-OH-E2 and 
4-OH-E2 in a ratio of 1 : 3 (Lee et al., 2003). The docking study suggests that CYP1A1 and 
CYP1A2 generate 2-OH-E2 rather than 4-OH-E2, and that CYP1B1 generates both 2-OH-E2 
and 4-OH-E2. Particular amino acids residues for each CYP were identified as playing an 
important role in estradiol recognition (Itoh et al., 2010). 
Several groups of phytochemicals were tested for affinity to active sites of CYP1 members. The 
first studied compounds were rutaecarpine derivatives. An alkaloid rutaecarpine preferentially 
inhibited CYP1A2 activity with IC50 value of 22 nM. However, 1-methoxyrutaecarpine and 1,2-
dimethoxyrutaecarpine were the most selective CYP1A2 inhibitors. Molecular modeling 
showed a good fitting of rutaecarpine and the active site of CYP1A2. Two hydrogen bonds 
between the keto- and N14-groups of rutaecarpine and the Thr208 and Thr473 residues of 
CYP1A2, respectively, were visualized with molecular modeling procedures. The C-ring 
moiety of rutaecarpine formed - stacking interaction with the aromatic ring of Phe205 
residue (Don et al., 2003).  
Coumarin was shown to be a substrate of human CYPs, specifically: CYP1A1 and CYP1A2. 
Molecular modeling led to recognition and localization of the amino acid residues which 
interact with coumarin molecules resulting in the orientation of coumarin with 3,4 bond 
directly above the heme moiety. Coumarin 3,4-epoxide is produced and then rearranged to 
hydroxyphenylacetaldehyde, which can be further metabolized to toxic products. In the 
CYP1A1 active site, Ser113 forms a hydrogen bond with coumarin, while Phe205 and Phe358 
are responsible for aromatic - stacking. In CYP1A2, Thr113 forms hydrogen bonds with 
coumarin, and Phe205 is responsible for - stacking (Lewis et al., 2006). However the 
different key residues take part in the interactions with coumarin, they determine the same 
site of metabolism, and in consequence, the pathway of coumarin metabolism is the same 
for both CYP1A1 and CYP1A2 . 
7,8-benzoflavone (-naphthoflavone) is a prototype flavonoid which has been used to 
examine the mechanism of action on P450 enzymes. Molecular modeling studies revealed 
that 7,8-naphthoflavone is positioned in a hydrophobic cavity of CYP1A2 next to the 
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active site where it may cause a direct effect on substrate binding (Cho et al., 2003). 
Further studies with the use of molecular docking were aimed at methoxyflavonoids with 
a 2–3 double bond, which exerted strong inhibitory effect on CYP1 activities, particularly 
CYP1B1 (Takemura et al., 2010). The authors observed that the binding specificity of 
methoxyflavonoids is based on the interactions between the methoxy groups and specific 
CYP1s residues. For example, chrysoeriol and isorhamnetin fit well into the active site of 
CYP1B1, but do not fit into the active site of CYP1A2 and 1A1 because of steric collisions 
between the methoxy substituent of these methoxyflavonoids and Ser122 in CYP1A1 and 
Thr124 in CYP1A2. Androutsopoulos’s group described molecular docking of several 
flavonoids with regard to their metabolism and inhibitory activity. The simulated binding 
orientation of the compounds tested was in accordance with the study of Takemura and 
coworkers (2010). Diosmetin and eupatorin are predicted to be oriented with ring-B over the 
prosthetic group so that 4’-methoxy group is at ~4.5 Ǻ from the heme iron. The less 
substituted chrysin and acacetin also were shown to bind CYP1A1 with ring-B over the iron-
heme group. However, a lower number of interactions were found within the active site of 
CYP1A1 (Androutsopoulos et al., 2011).  
To better characterize stilbenes as ligands of CYPs, we performed molecular docking by 
simulation of resveratrol and pterostilbene binding in active sites of CYP1A2 and CYP1B. 
Resveratrol and pterostilbene molecules were docked into the cavities of CYP1A2 (PDB 
code: 2hi4) and CYP1B1 (PDB code: 3pm0) with the use of the CDOCKER procedure 
implemented in Accelrys Discovery Studio 2.5.5. CDOCKER uses a CHARMm-based 
molecular dynamics (MD) scheme to dock ligands into a receptor binding site. For assigning 
receptor and ligand atom partial charges, we applied the charging rules used in the 
MMFF94 forcefield. Docked poses were scored by the negative value of CDOCKER energy 
for the –CDOCKER_ENERGY function, which include interaction energy and internal 
ligand energy: the higher positive value of –CDOCKER_ENERGY, the stronger affinity of a 
ligand to the binding site. 
Our docking experiment showed that in the CYP1A2 active site, all possible poses of 
resveratrol can be grouped into two sets. This observation indicated that two binding modes 
are possible for resveratrol molecule. In mode A, represented by the pose with highest score, 
a resveratrol molecule is directed with 4’-OH group toward a heme (Fig. 3a). In mode B, the 
second ring with 3-OH and 5-OH substituents is situated in the vicinity of a prosthetic 
group (Fig. 3b). In both orientations, resveratrol binding is stabilized by – stacking 
interactions, with phenyl ring of Phe226 (mode A), and with Phe226 and Phe260 (mode B). 
Contrary to resveratrol, a pterostilbene molecule was docked in the CYP1A2 active site only 
in one orientation with 4’-OH group directed toward a heme (Fig. 3c). Pterostilbene binding 
was stabilized by – interaction with an aromatic ring of Phe226 . For a resveratrol molecule 
docked in the active site of CYP1B1, we also distinguished two binding modes. In contrast to 
CYP1A2, the highest scored pose corresponded to binding mode B. In both orientations (A 
and B), resveratrol was stabilized by two – interactions between both of its rings and a 
phenyl ring of Phe231, and additionally by two hydrogen bonds with Asn265 and Asp333 in 
mode B, or Asn265 and Asn228 in mode A (Fig. 3d and 3e). 
Similar to interaction with CYP1A2, a pterostilbene molecule represented only one type of 
orientation in the CYP1B1 cavity (Fig. 2f). The binding conformation with 4’-OH group close 
to a heme was stabilized by two – stacking interactions with Phe231. In the case of 
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Fig. 3. Putative binding modes of resveratrol and pterostilbene in active sites of CYP1A2 (a – 
c) and CYP1B1 (d – f) with key residues involved in – stacking interactions and hydrogen 
bonds represented by solid blue lines and dashed blue lines, respectively. Heme molecule is 
at the bottom. CYP1A2 active site in complex with: (a) resveratrol in binding mode A, (b) 
resveratrol in mode B, (c) pterostilbene. CYP1B1 active site in complex with: (d) resveratrol 
in binding mode B, (e) resveratrol in mode A, (f) pterostilbene. 
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pterostilbene, which is a dimethoxy analogue of resveratrol, it is suggested that hydrophobic 
interactions might play a key role determining and stabilizing its docking orientation. 
In studies of trans-resveratrol metabolism by human microsomal CYP1B1 enzyme (Potter et 
al., 2002), the authors observed formation of two metabolites, M1 and M2. The major 
metabolite M2 has been identified as piceatannol (3,4,3',5'-tetrahydroxystilbene), while 
3,4,5,4'-tetrahydroxystilbene was proposed as the M1 product. More recent work (Piver et 
al., 2004) provided evidence that CYP1A2 is also engaged in the metabolism of trans-
resveratrol to piceatannol and tetrahydroxystilbene M1. Our studies confirmed the 
possibility of two pathways of metabolism on the grounds of molecular docking analysis. 
6. Conclusion 
The finding of high affinity ligands among natural compounds for each of the CYP1 family 
enzymes will help to reveal more about enzyme specificity, providing a starting point for 
more extensive studies and improved predictive capabilities. Particularly, a selective 
inhibition against CYP1B1 that influences the chemopreventive properties of 
phytochemicals for E2 related breast cancer seems to be promising. There is a need for better 
characterization of potential chemopreventive/therapeutic agents in order to understand 
their abilities and limits to influencing numerous pathways leading to cancer development. 
Novel classes of anti-cancer drugs including those of plant origin are being developed that 
can target both drug-metabolizing enzymes and disease modifying pathways. Recently, 
interest in the combinatory effect of different phytochemicals is growing, with respect to the 
multi-targeted action of numerous components of a food matrix. Wenzel and co-workers 
found that metabolism of resveratrol present in beverages such as wine or grape juice is 
inhibited by other polyphenols due to competitive reactions with Phase -II enzymes, 
resulting in an increased concentration of the free form (Wenzel et al., 2005). It is suggested 
that an efficient chemoprevention strategy lies in the use of combinations of several 
chemopreventive and/or therapeutic agents which may exert multi-targeted action. In 
conclusion, the search for potent and selective CYP1A inhibitors appears to hold promise 
and should be continued with the use of novel computational techniques. 
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